JP2022510410A5 - - Google Patents
Info
- Publication number
- JP2022510410A5 JP2022510410A5 JP2021531722A JP2021531722A JP2022510410A5 JP 2022510410 A5 JP2022510410 A5 JP 2022510410A5 JP 2021531722 A JP2021531722 A JP 2021531722A JP 2021531722 A JP2021531722 A JP 2021531722A JP 2022510410 A5 JP2022510410 A5 JP 2022510410A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776985P | 2018-12-07 | 2018-12-07 | |
| US62/776,985 | 2018-12-07 | ||
| US201962909147P | 2019-10-01 | 2019-10-01 | |
| US62/909,147 | 2019-10-01 | ||
| US201962926390P | 2019-10-25 | 2019-10-25 | |
| US62/926,390 | 2019-10-25 | ||
| PCT/US2019/065069 WO2020118252A1 (en) | 2018-12-07 | 2019-12-06 | Methods for treating castration-resistant and castration- sensitive prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510410A JP2022510410A (ja) | 2022-01-26 |
| JP2022510410A5 true JP2022510410A5 (https=) | 2022-11-29 |
| JPWO2020118252A5 JPWO2020118252A5 (https=) | 2022-11-29 |
Family
ID=70974424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531722A Pending JP2022510410A (ja) | 2018-12-07 | 2019-12-06 | 去勢抵抗性および去勢感受性前立腺がんを処置するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200281949A1 (https=) |
| EP (1) | EP3891294A4 (https=) |
| JP (1) | JP2022510410A (https=) |
| KR (1) | KR20210100145A (https=) |
| CN (1) | CN113164500A (https=) |
| AU (1) | AU2019395100A1 (https=) |
| CA (1) | CA3120850A1 (https=) |
| MX (1) | MX2021005075A (https=) |
| WO (1) | WO2020118252A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| ES2739749T3 (es) | 2015-05-18 | 2020-02-03 | Tolero Pharmaceuticals Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| US20190240198A1 (en) * | 2018-02-05 | 2019-08-08 | Dean G. Tang | Formulations and methods for the treatment of cancers |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| AU2021255723A1 (en) | 2020-04-17 | 2022-12-08 | Essa Pharma, Inc. | Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof |
| WO2022221661A1 (en) * | 2021-04-16 | 2022-10-20 | Essa Pharma, Inc. | Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof |
| WO2023114264A1 (en) * | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001080896A2 (en) * | 2000-04-21 | 2001-11-01 | Arch Development Corporation | Flavopiridol drug combinations and methods with reduced side effects |
| CN104812756A (zh) * | 2012-09-26 | 2015-07-29 | 曼凯德公司 | 多激酶通路抑制剂 |
| SG10201907684PA (en) * | 2013-01-15 | 2019-10-30 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
| WO2016033114A1 (en) * | 2014-08-25 | 2016-03-03 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
| ES2739749T3 (es) * | 2015-05-18 | 2020-02-03 | Tolero Pharmaceuticals Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| WO2018094275A1 (en) * | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| US11034710B2 (en) * | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
-
2019
- 2019-12-06 CN CN201980080943.0A patent/CN113164500A/zh active Pending
- 2019-12-06 WO PCT/US2019/065069 patent/WO2020118252A1/en not_active Ceased
- 2019-12-06 MX MX2021005075A patent/MX2021005075A/es unknown
- 2019-12-06 KR KR1020217020796A patent/KR20210100145A/ko not_active Withdrawn
- 2019-12-06 AU AU2019395100A patent/AU2019395100A1/en not_active Abandoned
- 2019-12-06 US US16/706,463 patent/US20200281949A1/en not_active Abandoned
- 2019-12-06 JP JP2021531722A patent/JP2022510410A/ja active Pending
- 2019-12-06 CA CA3120850A patent/CA3120850A1/en active Pending
- 2019-12-06 EP EP19893131.3A patent/EP3891294A4/en not_active Withdrawn
-
2021
- 2021-12-10 US US17/547,799 patent/US20220339172A1/en not_active Abandoned